SCD and fatty liver disease: Our results showed that the decreased TG content in the livers of WEA-treated rats (0.8 and 1.6 g/kg BW) might be attributed to the reduced hepatic expression of SREBP-1c, SCD1, FASN genes, and increased expression of the PPARα gene, suggesting that WEA ameliorates hepatic steatosis by decreasing lipogenesis and increasing fatty acid oxidation in a HFD-induced NAFLD rat model.